Nasser Azli is a medical oncologist with over 30 years of academic and pharmaceutical experience. As an expert in clinical oncology and drug development, Nasser Azli is a highly valuable addition to our Scientific Advisory Board, particularly in view of the upcoming first clinical trials of our drug candidate TL-532.
The new 300 sqm headquarters will support Tollys’ growth by offering all the features expected by biotech companies. This move to our new headquarters allows our team to work not only in our own research laboratories but also near the scientific and medical communities. This new space is specifically designed for biotech companies and will support our developments very efficiently.